FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767664492> ?p ?o ?g. }

• W2767664492 endingPage "558" @default.
• W2767664492 startingPage "550" @default.
• W2767664492 abstract "We previously demonstrated that matrine could inhibit the proliferating, migrating, as well as invading processes of both PC-3 and DU145 cells. However, the underlying molecular mechanisms have not yet been clearly defined. In this study, using various techniques such as high throughput sequencing technology, bioinformatics, quantitative real-time PCR, and immunoblot analysis, we aimed to understand whether matrine serves as a novel regulator of FOXO and PI3K-AKT signaling pathway. DU145 and PC-3 cell lines were cultured for 24 h in vitro. Cells were treated with either matrine or control serum for 48 h, followed by extraction of total RNA. The RNA was sequenced using HiSeq 2500 high-throughput sequencing platform (Illumina). A gene library was established and quality analysis of read data carried out. Integrated database from the website DAVID was used to analyze Gene Ontology (GO), and Kyoto encyclopedia of genes and genomes (KEGG) pathway of differential genes was used for pathway analysis, screening for fold differences of more than two times. The FOXO and PI3K-AKT signaling pathways were screened, and expression levels of mRNA and core protein detected by real-time PCR and immunoblotting, respectively. High throughput sequencing and GO analysis revealed that differentially expressed genes before and after treatment played an important role in cell metabolic process, growth process, anatomical structure formation, cellular component organization, and biological regulation. KEGG signal pathway analysis revealed that FOXO and PI3K-AKT signal pathways had a significant difference between before and after matrine-treated androgen-independent prostate cancer cells PC-3 and DU145. Real-time PCR showed that matrine treatment led to a significant increase in the expression levels of FOXO1A, FOXO3A, FOXO4, and FOXO6 in DU145 and PC-3 cells (P<0.01 or P<0.05), whereas the PI3K expression levels decreased (P<0.01). Similarly, immunoblotting revealed a significant increase (P<0.05) in the expression levels of FOXO1A FOXO3A, FOXO4, and FOXO6 in both PC-3 and DU145 cells, whereas PI3K expression levels decreased (P<0.05). Matrine had a broad regulating effect on the mRNA expression profiles of both PC-3 and DU145 cells. Matrine may inhibit cell proliferation, migration, as well as invasion, and induce apoptosis in both PC-3 and DU145 cells through FOXO and PI3K-AKT signaling pathways. Matrine could therefore be used as a complementary drug to present chemotherapeutic agents, for treating androgen-independent prostate cancer." @default.
• W2767664492 created "2017-11-17" @default.
• W2767664492 creator A5020746135 @default.
• W2767664492 creator A5022017179 @default.
• W2767664492 creator A5046516271 @default.
• W2767664492 creator A5060764750 @default.
• W2767664492 creator A5067985443 @default.
• W2767664492 creator A5077821675 @default.
• W2767664492 creator A5086701746 @default.
• W2767664492 date "2017-11-07" @default.
• W2767664492 modified "2023-10-01" @default.
• W2767664492 title "Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells" @default.
• W2767664492 cites W1560075141 @default.
• W2767664492 cites W1577826731 @default.
• W2767664492 cites W1820314031 @default.
• W2767664492 cites W1969735359 @default.
• W2767664492 cites W1983733795 @default.
• W2767664492 cites W1986896225 @default.
• W2767664492 cites W1992785642 @default.
• W2767664492 cites W1994138076 @default.
• W2767664492 cites W2012575856 @default.
• W2767664492 cites W2026283565 @default.
• W2767664492 cites W2032427485 @default.
• W2767664492 cites W2041771374 @default.
• W2767664492 cites W2061140647 @default.
• W2767664492 cites W2072009397 @default.
• W2767664492 cites W2076103389 @default.
• W2767664492 cites W2079009895 @default.
• W2767664492 cites W2088442622 @default.
• W2767664492 cites W2091616261 @default.
• W2767664492 cites W2095947085 @default.
• W2767664492 cites W2098845312 @default.
• W2767664492 cites W2100305481 @default.
• W2767664492 cites W2107804267 @default.
• W2767664492 cites W2108541764 @default.
• W2767664492 cites W2119034410 @default.
• W2767664492 cites W2132120580 @default.
• W2767664492 cites W2152239989 @default.
• W2767664492 cites W2166525118 @default.
• W2767664492 cites W2218153549 @default.
• W2767664492 cites W2235523093 @default.
• W2767664492 cites W2272984102 @default.
• W2767664492 cites W2915478882 @default.
• W2767664492 doi "https://doi.org/10.1007/s11427-016-9050-6" @default.
• W2767664492 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29119376" @default.
• W2767664492 hasPublicationYear "2017" @default.
• W2767664492 type Work @default.
• W2767664492 sameAs 2767664492 @default.
• W2767664492 citedByCount "23" @default.
• W2767664492 countsByYear W27676644922018 @default.
• W2767664492 countsByYear W27676644922019 @default.
• W2767664492 countsByYear W27676644922020 @default.
• W2767664492 countsByYear W27676644922021 @default.
• W2767664492 countsByYear W27676644922022 @default.
• W2767664492 countsByYear W27676644922023 @default.
• W2767664492 crossrefType "journal-article" @default.
• W2767664492 hasAuthorship W2767664492A5020746135 @default.
• W2767664492 hasAuthorship W2767664492A5022017179 @default.
• W2767664492 hasAuthorship W2767664492A5046516271 @default.
• W2767664492 hasAuthorship W2767664492A5060764750 @default.
• W2767664492 hasAuthorship W2767664492A5067985443 @default.
• W2767664492 hasAuthorship W2767664492A5077821675 @default.
• W2767664492 hasAuthorship W2767664492A5086701746 @default.
• W2767664492 hasBestOaLocation W27676644921 @default.
• W2767664492 hasConcept C104317684 @default.
• W2767664492 hasConcept C121608353 @default.
• W2767664492 hasConcept C150194340 @default.
• W2767664492 hasConcept C152724338 @default.
• W2767664492 hasConcept C162317418 @default.
• W2767664492 hasConcept C169760540 @default.
• W2767664492 hasConcept C2776438761 @default.
• W2767664492 hasConcept C2776545273 @default.
• W2767664492 hasConcept C2779723316 @default.
• W2767664492 hasConcept C2780192828 @default.
• W2767664492 hasConcept C54355233 @default.
• W2767664492 hasConcept C62478195 @default.
• W2767664492 hasConcept C70721500 @default.
• W2767664492 hasConcept C75217442 @default.
• W2767664492 hasConcept C86554907 @default.
• W2767664492 hasConcept C86803240 @default.
• W2767664492 hasConcept C95444343 @default.
• W2767664492 hasConceptScore W2767664492C104317684 @default.
• W2767664492 hasConceptScore W2767664492C121608353 @default.
• W2767664492 hasConceptScore W2767664492C150194340 @default.
• W2767664492 hasConceptScore W2767664492C152724338 @default.
• W2767664492 hasConceptScore W2767664492C162317418 @default.
• W2767664492 hasConceptScore W2767664492C169760540 @default.
• W2767664492 hasConceptScore W2767664492C2776438761 @default.
• W2767664492 hasConceptScore W2767664492C2776545273 @default.
• W2767664492 hasConceptScore W2767664492C2779723316 @default.
• W2767664492 hasConceptScore W2767664492C2780192828 @default.
• W2767664492 hasConceptScore W2767664492C54355233 @default.
• W2767664492 hasConceptScore W2767664492C62478195 @default.
• W2767664492 hasConceptScore W2767664492C70721500 @default.
• W2767664492 hasConceptScore W2767664492C75217442 @default.
• W2767664492 hasConceptScore W2767664492C86554907 @default.
• W2767664492 hasConceptScore W2767664492C86803240 @default.
• W2767664492 hasConceptScore W2767664492C95444343 @default.

• next